氯吡格雷联合阿司匹林治疗急性非致残性脑血管病的临床观察

目的观察氯吡格雷联合阿司匹林组与单独应用阿司匹林组在降低急性非致残性缺血性卒中或短暂脑缺血发作(TIA)患者3个月内出现缺血性卒中的风险的作用以及其安全性。方法将259例非致残性缺血性卒中或TIA患者随机分为阿司匹林联合氯吡格雷组和单独使用阿司匹林组,分别观察其90d内发生主要终点事件(新发缺血性卒中)及次要终点事件(TIA、心肌梗死或血管性死亡)的情况,以及两组间的安全性差异。结果氯吡格雷联合阿司匹林组发生主要终点事件7例,次要终点事件4例,分别占5.3%、3.1%;阿司匹林组发生主要终点事件16例,次要终点事件5例,分别占12.5%、3.9%。两组间比较主要终点事件差异具有统计学意义(P<0.05),次要终点事件差异无统计学意义(P>0.05)。两组间出血不良事件的发生率差异无统计学意义(P>0.05)。结论氯吡格雷联合阿司匹林组相比单用阿司匹林组,能有效减少主要终点事件发生率,而不增加出血风险。

Observation of curative effect about aspirin and clopidogrel in acute non-disabling cerebrovascular events

Objective To observe the effect and safety of aspirin and clopidogrel in treating acute non-disabling cerebrovascular events.Methods 259 patients with acute non-disabling cerebrovascular events were enrolled in this study and distributed into two groups.129 patients were given aspirin,and the others were given aspirin and clopidogrel.The primary outcome was ischaemic stroke within 90 days.The secondary outcomes included TIA,MI and vascular death.We need to observe how many pesrons happened these events above-mentioned,and the differences of safety between two groups.Results Among patients randomised to aspirin and clopidogrel,7(5.3%) patients experienced a ischaemic stroke and 4(3.1%) experienced a TIA compared with 16(12.5%) and 5(3.9%) of patients with aspirin.There was a significant difference in the primary outcome(P<0.05),but no significant difference in secondary outcomes and safety(P>0.05).Conclusion Aspirin and clopidogrel were effective and safe in the treatment of acute non-disabling cerebrovascular events.